Roneparstat is under clinical development by Leadiant Biosciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Roneparstat’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Roneparstat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Roneparstat overview

Roneparstat (SST-0001) is under development for the treatment of advanced refractory multiple myeloma and plasma cell myeloma. The drug candidate is administered through subcutaneous route. It is a N-acetylated and glycol split heparin that acts by targeting heparanase enzyme. It was also under development for the treatment of Ewing's Sarcoma, lymphomas, soft tissue sarcoma, bone sarcomas and bone metastasis.

Leadiant Biosciences overview

Leadiant Biosciences, formerly Sigma-Tau Pharmaceuticals, is a pharmaceutical company. It discovers and develops novel medicines. The company provides products such as abelcet, adagen, carnitor, cystaran, depocyt, matulane and revcovi, among others. It also offers services including patient support, discovery and development of novel medicines for the unmet needs of patients with rare diseases. Leadiant Biosciences conducts research and development for the treatment of cerebrotendinous xanthomatosis, adenosine deaminase severe combined immunodeficiency, necrotizing enterocolitis and GNE myopathy. The company markets its products through a network of distributors in the US and abroad. Leadiant Biosciences is headquartered in Gaithersburg, Maryland, the US.

Quick View Roneparstat LOA Data

Report Segments
  • Innovator
Drug Name
  • Roneparstat
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.